“I buy on the assumption that they could close the market the next day and not reopen it for five years.”
— Warren Buffett
A five-year holding period can offer a clearer view of a stock’s underlying performance than short-term market swings. In the case of Incyte Corporation (NASD: INCY), a $10,000 investment made in July 2021 and held through early July 2026 grew to $14,024.26. That equates to a total return of 40.22% and an annualized return of 7.01%.
Because Incyte does not pay a dividend, this five-year return reflects share-price appreciation alone rather than a combination of capital gains and reinvested income. That makes the result especially useful for evaluating how the market repriced the business over time.
INCY 5-Year Return Details
| Start date: | 07/06/2021 |
|
|||
| End date: | 07/02/2026 | ||||
| Start price/share: | $83.34 | ||||
| End price/share: | $116.86 | ||||
| Starting shares: | 119.99 | ||||
| Ending shares: | 119.99 | ||||
| Dividends reinvested/share: | $0.00 | ||||
| Total return: | 40.22% | ||||
| Average annual return: | 7.01% | ||||
| Starting investment: | $10,000.00 | ||||
| Ending investment: | $14,024.26 | ||||
What Drove the Incyte Stock Return?
The five-year gain was generated entirely by a higher share price, rising from $83.34 to $116.86. Since Incyte did not distribute dividends during the period, investors participated through capital appreciation only. That matters when comparing INCY with pharmaceutical or biotechnology peers that return cash through dividends or buybacks, because the shareholder return profile is different.
Incyte is a biotechnology company best known for its hematology and oncology focus, with commercial exposure anchored by Jakafi. For a stock like INCY, long-term returns often depend on a small number of durable drivers:
- Commercial execution: Revenue durability in established products can support valuation even when the broader biotech market is volatile.
- Pipeline progress: Clinical updates, regulatory milestones, and label expansions can materially change long-run expectations.
- Capital allocation: For non-dividend-paying biotech companies, returns depend more heavily on reinvestment discipline and the market’s confidence in future cash flows.
- Patent and competitive dynamics: The market continually reassesses exclusivity, competitive entry, and the sustainability of core franchises.
Quick Takeaways From This 5-Year Holding Period
For investors reviewing Incyte’s five-year performance, the key points are straightforward:
- Initial investment: $10,000
- Ending value: $14,024.26
- Total return: 40.22%
- Annualized return: 7.01%
- Dividend contribution: None
Those figures indicate a respectable, if not extraordinary, compound return over the period. They also illustrate an important feature of biotech investing: even when the end result is positive, the path can be shaped by changing expectations around drug portfolios, development pipelines, and market sentiment toward the sector.
Why the 5-Year View Matters
Shorter measurement windows can be dominated by macro shocks, sector rotations, or single-event volatility. A five-year period is long enough to capture more of the business cycle, multiple reporting periods, and a broader set of strategic developments. For Incyte, that longer frame helps separate transient price fluctuations from the market’s evolving assessment of the company’s earnings power and pipeline value.
It also provides a cleaner basis for comparison. A stock that produces a mid-single-digit to high-single-digit annualized return without dividend support is relying on the market to steadily assign more value to the underlying enterprise. That is a different investment profile from companies where a large share of total return comes from cash distributions.
The above numbers were computed with the Dividend Channel DRIP Returns Calculator.
“Your investor’s edge is not something you get from Wall Street experts. It’s something you already have. You can outperform the experts if you use your edge by investing in companies or industries you already understand.” — Peter Lynch
